Promising cocktail may shrink pancreatic tumors before surgery
NCT ID NCT01821729
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase II trial tested a combination of chemotherapy drugs (FOLFIRINOX) plus the blood pressure drug losartan, followed by proton radiation, in 50 people with locally advanced pancreatic cancer. The goal was to see if this approach could shrink tumors enough to allow complete surgical removal. The study focused on safety and how many patients achieved a clean surgical margin.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FOLFIRINOX (combination of 5-fluorouracil, leucovorin, oxaliplatin, irinotecan), losartan, capecitabine, and proton beam radiation
What this could lead to
If successful, this combination could improve the chance of surgically removing pancreatic tumors with clear margins, potentially extending survival.
What could go wrong
This is a small Phase II study with only 50 participants, so results may not apply broadly. The combination has significant side effects and may not improve outcomes over standard therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States